Boston Scientific Corp. Hits New 52-Week Low at $44.80

Boston Scientific Corp. has reached a significant milestone by touching a new 52-week low of USD 44.80 on June 17, 2026. This decline reflects a challenging year for the company, with its stock performance down 41.94% over the past year, contrasting sharply with the S&P 500's gain of 24.03%. As a large-cap player in the retailing industry, Boston Scientific Corp. holds a market capitalization of USD 120,852 million. The company's price-to-earnings (P/E) ratio stands at 36.00, indicating how the market values its earnings relative to its share price. Additionally, the company has a debt-to-equity ratio of 0.39, suggesting a moderate level of debt compared to its equity. Despite the current low price, Boston Scientific's return on equity is reported at 13.88%, and it maintains a price-to-book ratio of 4.99. The absence of a dividend yield indicates that the company is likely reinvesting its earnings back into the business. This recent price movement highlights the ongoing dynamics within the retailing sector and the company's current market position.